Literature DB >> 30995172

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

Antonio Passaro1, Gianluca Spitaleri1, Bishal Gyawali2,3, Filippo de Marinis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30995172     DOI： 10.1200/JCO.18.02118

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  30 in total

Review 1.  Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.

Authors:  Alex Friedlaender; Giuseppe Luigi Banna; Lucio Buffoni; Alfredo Addeo
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

2.  Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models.

Authors:  Xinsong Du; Jae Min; Chintan P Shah; Rohit Bishnoi; William R Hogan; Dominick J Lemas
Journal:  Int J Med Inform       Date:  2020-04-15       Impact factor: 4.046

3.  Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.

Authors:  Filippo Pietrantonio; Fotios Loupakis; Giovanni Randon; Alessandra Raimondi; Massimiliano Salati; Dario Trapani; Filippo Pagani; Ilaria Depetris; Giulia Maddalena; Federica Morano; Salvatore Corallo; Michele Prisciandaro; Francesca Corti; Vincenzo Guarini; Alessandro Bocconi; Antonio Marra; Carmen Belli; Andrea Spallanzani; Matteo Fassan; Sara Lonardi; Giuseppe Curigliano; Giovanni Fucà; Maria Di Bartolomeo; Filippo de Braud
Journal:  Oncologist       Date:  2020-05-20

4.  The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly.

Authors:  Johan Chan; Ravindran Kanesvaran
Journal:  Ann Transl Med       Date:  2019-12

5.  KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?

Authors:  Jose M Pacheco
Journal:  Transl Lung Cancer Res       Date:  2019-10

6.  Real-World Evidence in Oncology: Opportunities and Limitations.

Authors:  Massimo Di Maio; Francesco Perrone; Pierfranco Conte
Journal:  Oncologist       Date:  2019-12-24

Review 7.  Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.

Authors:  Vishal Navani; Moira C Graves; Nikola A Bowden; Andre Van Der Westhuizen
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

8.  The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis.

Authors:  Yafei You; Chang Jiang; Kunwei Peng; Wenzhuo He; Lei Wang; Yanan Jin; Liangping Xia
Journal:  Cancer Immunol Immunother       Date:  2021-01-29       Impact factor: 6.968

9.  SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

Authors:  Michael Mark; Patrizia Froesch; Eric Innocents Eboulet; Alfredo Addeo; Miklos Pless; Sacha I Rothschild; Wolf-Dieter Janthur; Henning Burmeister; Alex Friedlaender; Martina Schneider; Yannis Metaxas; Markus Joerger; Luciano Wannesson; Michael Schwitter; Nathalie Baudoux; Susanne Weindler; Christine Biaggi-Rudolf; Martin Früh
Journal:  Cancer Immunol Immunother       Date:  2020-11-01       Impact factor: 6.968

10.  Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.

Authors:  Laura A Petrillo; Kerry L Reynolds; Sienna M Durbin; Leyre Zubiri; Andrzej Niemierko; Aditya Bardia; Ryan J Sullivan; Corey McEwen; Therese M Mulvey; Ian M Allen; Donald P Lawrence; Justine V Cohen; Ephraim P Hochberg; David P Ryan
Journal:  Oncologist       Date:  2020-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.